The traditional treatment of tumor includes surgery, chemotherapy, radiotherapy and biological therapy, etc. Interventional treatment of tumor has the advantages of minimally invasive, low cost, safety and good efficacy, especially for those tumor patients who cannot be operated, which shows its status in tumor treatment more and more. Tumor interventional therapy can be divided into two categories: transvascular and non-transvascular: transvascular tumor interventional therapy includes: arterial perfusion chemotherapy and arterial embolization. Non-transvascular tumor interventional therapy can be broadly divided into: 1. Such as percutaneous intra-tumor injection of anhydrous alcohol, dilute hydrochloric acid or other chemotherapeutic drugs; percutaneous puncture for radiofrequency ablation, microwave ablation and argon helium knife treatment of tumor. 2.Tumor resection or ablation by endoscopy, or injection drug treatment, etc. Interventional therapy for liver cancer is an important part of tumor treatment, especially it has become one of the main methods of interventional therapy for liver cancer because of its good efficacy. The following liver cancer patients are all feasible for hepatocellular interventional therapy: (1) primary or metastatic liver cancer which is considered inoperable for various reasons, or small liver cancer which patients are unwilling to operate. (2) As a preparation before surgery, liver cancer can be shrunk through interventional treatment, which makes surgery easy to resect, and in addition, the spread and recurrence of tumor can be reduced after intervention. (3) Patients with incomplete resection of hepatocellular carcinoma, postoperative recurrence or failure of other methods of treatment. (4) The liver cancer lesion does not rupture and bleed. (5) No serious impairment of liver or kidney function. (6) Patients without severe jaundice and ascites. (7) Patients with good general condition and no serious bleeding disease. The effectiveness of hepatocellular carcinoma intervention is determined by the characteristics of blood supply of hepatocellular carcinoma. Normally, the liver is supplied with blood by hepatic artery and portal vein, of which portal vein supply accounts for 75% to 80% and hepatic artery supply accounts for 20% to 25%. The blood supply of hepatocellular carcinoma is exactly the opposite, with more than 90% to 95% of the blood supply from hepatic artery and very little blood supply from portal vein. This brings convenience to the treatment. Through hepatic artery cannulation, drugs can directly enter liver cancer tissues to increase the local drug concentration and kill cancer cells. In addition, some embolic substances such as iodine oil and gelatin sponge are applied to embolize the blood supply artery of liver cancer to cut off its nutritional effect, and the tumor tissues will be necrosed, thus achieving the purpose of treatment. In general, one or more times of minimally invasive interventional treatment is feasible. With the rapid development of medical science and imaging equipment, surgery may be partially replaced by local treatment in the treatment of small liver cancer; in the treatment of large liver cancer, with the progress of local treatment, surgery will play a greater role in resection after reduction, and interventional treatment methods for liver cancer will be of great importance. With the breakthroughs in nanotechnology, nanoparticle-drug complexes can be infused into hepatic arteries using nanotechnology to achieve targeting effects in the future interventional treatment of liver cancer, and the combination of nanotechnology and molecular biology technology will also be a hot spot for future medical research. In addition, with the continuous development and application of angiogenesis inhibitors and the research of genes related to apoptosis of liver cancer cells, gene therapy and anti-tumor vascular therapy will definitely bring gospel to liver cancer patients. Intra-arterial infusion of anticancer drugs alone has low efficacy and high response, and the use of microcatheters for super-selective and segmental embolization is also a future development direction when conditions permit. The application of Chinese anticancer agents in hepatocellular carcinoma interventions and the application of new embolic agents such as drug-containing microspheres 90y glass spheres need to be further developed and promoted. Continuous infusion of biochemotherapy drugs via implantable drug cartridge catheter system has a bright clinical application prospect for removing residual cancer cells and reducing recurrence rate.